Does Carbidopa Interact with Fluorodopa F18?
Carbidopa and Fluorodopa F18 have a moderate drug interaction according to U.S. FDA drug labeling data. AADC inhibitor that may increase Fluorodopa F18 bioavailability to the brain by inhibiting peripheral decarboxylase activity. The mechanism involves inhibition of peripheral decarboxylase activity. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Carbidopa Class
- Aromatic Amino Acid Decarboxylation Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Carbidopa and Fluorodopa F18 occurs because inhibition of peripheral decarboxylase activity. Clinically, this means aadc inhibitor that may increase fluorodopa f18 bioavailability to the brain by inhibiting peripheral decarboxylase activity. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Carbidopa and your doctor is considering prescribing Fluorodopa F18 (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider